Search results for "Subcutaneous"

showing 10 items of 162 documents

Improved effect of the combination naltrexone/D-penicillamine in the prevention of alcohol relapse-like drinking in rats

2014

Opioid antagonists are licensed drugs for treating alcohol use disorders; nonetheless, clinical studies have evidenced their limited effectiveness. Preclinical findings indicate that opioid receptor (OR) antagonists, such as naltrexone (NTX), reduce the alcohol deprivation effect (ADE). However, a detailed analysis of published data shows the existence of a delayed increase in ethanol consumption after continuous OR blockade, a phenomenon originally called as ‘delayed ADE’. We have recently reported that D-penicillamine (DP) is able to prevent ADE through a mechanism dependent on the inactivation of acetaldehyde, the main metabolite of ethanol. Hypothetically, OR activation would be trigge…

MaleCombination therapyAlcohol Drinkingmedicine.drug_classInjections SubcutaneousNarcotic AntagonistsPharmacologyInfusions SubcutaneousNaltrexoneethanol relapse preventionchemistry.chemical_compoundOpioid receptormedicineSecondary PreventionAnimalsPharmacology (medical)PharmacologyEthanolbusiness.industryPenicillaminePenicillamineD-penicillamineAcetaldehydeNaltrexoneRatsPsychiatry and Mental healthOpioidchemistrymu-opioid receptorDrug Therapy Combinationμ-opioid receptorbusinessnaltrexonehuman activitiesmedicine.drugAlcohol Deterrentsacetaldehyde
researchProduct

Evaluation of intraindividual contrast enhancement variability for determining the maximum achievable consistency in CT

2019

OBJECTIVE. The purpose of this study was to quantify temporal variability in vascular and parenchymal enhancement within the same patient and to determine technique-related factors contributing to this variability. MATERIALS AND METHODS. We identified 100 patients who underwent four CT scans within 12 months with identical acquisition and contrast injection parameters. Enhancement was recorded in the abdominal aorta, main portal vein, liver parenchyma, and subcutaneous fat. Patient demographic and body habitus data were recorded. Injection-related factors were recorded including delay time from contrast injection to image acquisition. All pairwise differences in enhancement within each pati…

MaleContrast enhancementTime Factors030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineConsistency (statistics)MedicineHumansRadiology Nuclear Medicine and imagingAorta AbdominalVariabilityAgedRetrospective StudiesObserver Variationbusiness.industryPortal VeinEnhancementContrast mediaGeneral MedicineMiddle AgedSubcutaneous Fat AbdominalRadiographic Image EnhancementLiver030220 oncology & carcinogenesisFemalebusinessNuclear medicineTomography X-Ray ComputedCT
researchProduct

Higher Free Fatty Acid Uptake in Visceral Than in Abdominal Subcutaneous Fat Tissue in Men

2010

Visceral adipose tissue has been shown to have high lipolytic activity. The aim of this study was to examine whether free fatty acid (FFA) uptake into visceral adipose tissue is enhanced compared to abdominal subcutaneous tissue in vivo. Abdominal adipose tissue FFA uptake was measured using positron emission tomography (PET) and [F-18]-labeled 6-thia-hepta-decanoic acid ([F-18]FTHA) and fat masses using magnetic resonance imaging (MRI) in 18 healthy young adult males. We found that FFA uptake was 30% higher in visceral compared to subcutaneous adipose tissue (0.0025 +/- 0.0018 vs. 0.0020 +/- 0.0016 mu mol/g/min, P = 0.005). Visceral and subcutaneous adipose tissue FFA uptakes were strongly…

MaleEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Adipose tissueWhite adipose tissueFatty Acids NonesterifiedGLUCOSE0302 clinical medicineEndocrinologyReference ValuesIN-VIVOchemistry.chemical_classification0303 health sciencesINSULIN-RESISTANCENutrition and DieteticsFatty AcidsMagnetic Resonance Imagingmedicine.anatomical_structureADIPOSE-TISSUEPROLONGED EXERCISESKELETAL-MUSCLESubcutaneous tissueAdultmedicine.medical_specialtyIntra-Abdominal Fat030209 endocrinology & metabolismIntra-Abdominal FatMETABOLISMYoung Adult03 medical and health sciencesInsulin resistanceInternal medicinemedicineHumansTotal TissueINCREASED PHYSICAL-ACTIVITY030304 developmental biologyBLOOD-FLOWbusiness.industryFatty acidSkeletal muscleBiological Transportmedicine.diseaseSubcutaneous Fat AbdominalEndocrinologychemistryPositron-Emission TomographyRadiopharmaceuticalsbusinessMYOCARDIUMObesity
researchProduct

Modeling human osteosarcoma in mice through 3AB‐OS cancer stem cell xenografts

2012

Osteosarcoma is the second leading cause of cancer-related death for children and young adults. In this study, we have subcutaneously injected—with and without matrigel—athymic mice (Fox1nu/nu) with human osteosarcoma 3AB-OS pluripotent cancer stem cells (CSCs), which we previously isolated from human osteosarcoma MG63 cells. Engrafted 3AB-OS cells were highly tumorigenic and matrigel greatly accelerated both tumor engraftment and growth rate. 3AB-OS CSC xenografts lacked crucial regulators of beta-catenin levels (E-cadherin, APC, and GSK-3beta), and crucial factors to restrain proliferation, resulting therefore in a strong proliferation potential. During the first weeks of engraftment 3AB-…

MaleIntegrin beta ChainsXENOGRAFTNudeAnimals; Bone Neoplasms; Collagen; Drug Combinations; Focal Adhesion Kinase 1; Gene Expression Regulation Neoplastic; Humans; Injections Subcutaneous; Integrin beta Chains; Laminin; Male; Mice; Mice Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Osteosarcoma; Pluripotent Stem Cells; Proteoglycans; Proto-Oncogene Proteins c-akt; Signal Transduction; Transplantation Heterologous; Tumor Markers Biological3AB-OS CSCSBiochemistryMiceInduced pluripotent stem cellTumor MarkersOsteosarcomaHeterologousSubcutaneousXIAPGene Expression Regulation NeoplasticDrug CombinationsANIMAL MODELSNeoplastic Stem CellsOsteosarcomaProteoglycansCollagenMATRIGELSignal TransductionPluripotent Stem CellsInjections SubcutaneousTransplantation HeterologousMice NudeBone NeoplasmsBiologyInjectionsCyclin D2Cancer stem cellBiomarkers TumormedicineAnimalsHumansMolecular BiologyProtein kinase BNeoplasticTransplantationMatrigelMesenchymal stem cellCell BiologyBiologicalmedicine.disease3AB-OS CSCS; OSTEOSARCOMA; XENOGRAFT; MATRIGEL; ANIMAL MODELSGene Expression RegulationFocal Adhesion Kinase 1ImmunologyCancer researchLamininProto-Oncogene Proteins c-aktNeoplasm TransplantationJournal of Cellular Biochemistry
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

MATRICES OF A HYDROPHOBICALLY FUNCTIONALIZED HYALURONIC ACID DERIVATIVE FOR THE LOCOREGIONAL TUMOUR TREATMENT

2015

A hyaluronic acid (HA) derivative bearing octadecylamine and acylhydrazine functionalities has been here employed for the production of a paclitaxel delivering matrix for locoregional chemotherapy. Through a strategy consisting in a powder compression and a plasticization with a mixture water/ethanol, a physically assembled biomaterial, stable in solutions with physiologic ionic strengths, has been produced. Two different drug loading strategies have been adopted, by using paclitaxel as chemotherapic agent, and obtained samples have been assayed in terms of release in enhanced solubility conditions and in vitro and in vivo tumoural cytotoxicity. In particular sample with the best releasing …

MaleMaterials sciencePaclitaxelBiomedical EngineeringMice NudeBiocompatible MaterialsBiochemistryPaclitaxel release matrices hyaluronic acidBiomaterialschemistry.chemical_compoundMiceSubcutaneous TissueIn vivoNeoplasmsHyaluronic acidAnimalsHumansSolubilityHyaluronic AcidCytotoxicityMolecular BiologyCell DeathHydrolysisBody WeightOsmolar ConcentrationAcylhydrazineBiomaterialGeneral MedicineHCT116 CellsImmunohistochemistryXenograft Model Antitumor AssaysIn vitroPaclitaxelchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoHydrophobic and Hydrophilic InteractionsBiotechnologyBiomedical engineeringNuclear chemistry
researchProduct

The cytotoxic evaluation of mineral trioxide aggregate and bioaggregate in the subcutaneous connective tissue of rats

2013

Objectives: The purpose of this study was to evaluate and compare the cytotoxic effects of ProRoot MTA and DiaRoot BA, a bioceramic nanoparticulate cement, on subcutaneous rat tissue. Study D esign: Fifty Sprouge Dawley rats were used in this study. Polyethylene tubes filled with ProRoot MTA and DiaRoot BioAggregate, along with a control group of empty, were implanted into dorsal connective tissue of rats for 7, 15, 30, 60, and 90 days. After estimated time intervals the rats were sacrificed. The specimens were fixed, stained with hematoxylin and eosin, and then evaluated under a light microscope for inflammatory reactions and mineralization. Results: All groups evoked a severe to moderate …

MaleMineral trioxide aggregateNecrosisSubcutaneous connective tissueH&E stainDentistryConnective tissueOdontologíaEndodonticsCalcium HydroxideRats Sprague-DawleyRoot Canal Filling MaterialsAndrologyBioAggregateSubcutaneous TissueFibrosisMaterials TestingmedicineAnimalsCytotoxic T cellAluminum CompoundsGeneral DentistryChemistrybusiness.industrySilicatesOxidesCalcium Compounds:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludRatsDrug Combinationsmedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASResearch-ArticleSurgeryHydroxyapatitesmedicine.symptombusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Comparison of two histopathologic methods for evaluating subcutaneous reaction to mineral trioxide aggregate

2011

Objectives: One of the most important factors for suitable materials for pulp therapy is biocompatibility. Two histopathologic methods of Cox and Federation Dentaire International (FDI) were used to evaluate inflammation. In Cox method, density of inflammatory cells, tissue reactions like fibrosis, vascular responses like congestion and fibrin extravasation have been used to evaluate inflammatory reactions. The aim of this study was to compare the accuracy of pathologists’ interpretations using two different methods. Study design: Three pathologists observed the degree of inflammation in 225 histopathologic sections. These sections showed inflammation in subcutaneous connective tissue of ra…

MaleMineral trioxide aggregatePathologymedicine.medical_specialtySubcutaneous connective tissueConnective tissueRoot Canal Filling MaterialsSubcutaneous TissueFibrosismedicineAnimalsRats WistarAluminum CompoundsGeneral DentistryInflammationOral Medicine and PathologyPathology ClinicalKappa valuebusiness.industrySilicatesOxidesCalcium Compounds:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseExtravasationRatsDrug Combinationsmedicine.anatomical_structureOtorhinolaryngologyPulp therapyUNESCO::CIENCIAS MÉDICASResearch-ArticleSurgerybusinessSubcutaneous tissue
researchProduct

Cheek Volumization and the Nasolabial Fold.

2018

Sir: We have read the article by Mowlds and Lambros1 with great interest and enthusiasm. The findings of their study show that the nasolabial fold does not improve after cheek injection. By analyzing three-dimensional images of the face before and immediately after cheek injection of high- G′ hyaluronic acid, they demonstrate that the perceived nasolabial fold improvement, reported after cheek injections,2,3 is attributable to overall improvement in facial appearance rather than to actual nasolabial fold improvement. As a consequence, it might be ruled out that the nasolabial fold is a consequence of cheek deflating and it is likely attributable predominantly to change in the corner of the …

MaleNasolabial FoldInjections SubcutaneousSettore MED/19 - Chirurgia PlasticaFacial MusclesAdipose tissueCosmetic Techniques030230 surgery030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineImaging Three-DimensionalDermal FillersmedicineImage Processing Computer-AssistedPhotographyHumansHyaluronic AcidInjections subcutaneousOrthodonticsbusiness.industryAnatomyCheekNasolabial foldFacial MuscleFacial Expressionstomatognathic diseasesFacial musclesmedicine.anatomical_structureCheekAdipose Tissue030220 oncology & carcinogenesisSurgeryFemalebusinessPlastic and reconstructive surgery
researchProduct

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

2008

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictiv…

MaleNeutralising antibodyMULTICENTERPLACEBO-CONTROLLED TRIALGUIDELINESGastroenterologyDOUBLE-BLINDInterferon βMAGNETIC-RESONANCEProspective StudiesNeurologic ExaminationbiologyBrainIMPAIRMENTMiddle AgedPredictive valueMagnetic Resonance ImagingRecombinant ProteinsPsychiatry and Mental healthTreatment OutcomeSettore MED/26 - NeurologiaFemaleAntibodyInterferon beta-1bAdultmedicine.medical_specialtyDIAGNOSTIC-CRITERIAInjections SubcutaneousAntibodiesDrug Administration ScheduleDisease activityMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicNeutralization TestsInternal medicinemedicineHumansInterferon betabusiness.industryMultiple sclerosisDISABILITYMSInterferon-betamedicine.diseaseConfidence intervalSurgerybiology.proteinSurgeryNeurology (clinical)businessFollow-Up Studies
researchProduct